Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian ...

Several ASX-listed companies have partnered with Cell Therapies, based at Peter Mac to manufacture CAR-T and other cell ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

Inspired by the world's great Lego Masters, Arovella is taking a brick-by-brick approach to building its unique cancer immunotherapy program.

This transformative model leads to better long-term health outcomes while reducing the need for pharmaceuticals or surgical solutions. AMSA Biotech offers customized treatment plans that utilize ...

Cancer is the rapid, uncontrollable proliferation of mutated cells that spread within tissue and eventually throughout the body. Cancer types are dependent | Immunology ...

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...